nyra health is a technology company.
nyra health has raised $5.0M across 1 funding round.
nyra health has raised $5.0M in total across 1 funding round.
nyra health is a Vienna-based technology company developing AI-powered digital neurotherapy solutions for patients with neurological conditions like stroke, dementia, and long COVID.[1][2][4][5] Its flagship product, the CE-certified myReha app (tablet-based), delivers personalized speech, language, and cognitive therapy through over 65,000 interactive exercises, adapting via machine learning analysis of speech patterns and biomarkers; a companion web platform, nyra.insights, tracks progress from diagnosis onward for clinics and patients.[1][2][3][6] Serving clinics, practices, patients at home (tele-rehab), and health insurers, it addresses therapy access gaps by providing scalable, evidence-based care—used by over 100 clinics, 50,000+ patients, with 98% satisfaction and 93% stronger improvements vs. standard therapy.[3][6] Recently rebranded from myReha, it raised a €4.5M oversubscribed seed round in 2024 co-led by MassMutual Ventures and Wellington Partners to expand in DACH and English-speaking markets.[2]
nyra health was founded in 2020 in Vienna, Austria, by an interdisciplinary team led by Dr. Philipp Schöllauf, a neurologist experienced in stroke rehabilitation who identified the challenge of patients losing progress post-discharge due to limited access.[1][4][5] He partnered with Mario Zusag, a machine learning researcher from Google AI and IBM Research, and Moritz Schöllauf, a lawyer specializing in regulatory affairs, collaborating with speech therapists, neuropsychologists, and ML experts to build the myReha app as a digital therapy platform.[1][5] Pivotal early traction came from over 45 hospital customers in Germany and Austria, delivering 3+ hours of weekly therapy per patient, with thousands using it for home tele-rehab; this led to the 2024 rebrand to nyra health alongside its €4.5M seed funding.[2][3]
nyra health rides the aging population-driven surge in neurological disorders (e.g., stroke, dementia), projected to rise >50% by 2050, amid resource shortages in rehab—too few staff, limited access.[2][5] Its timing aligns with AI-healthcare convergence, scaling personalized therapy where traditional methods fall short, enhanced by post-COVID telehealth momentum.[1][6] Market forces like insurer reimbursements (e.g., German DRV) and DACH expansion favor it, while influencing ecosystems via clinic integrations that boost care quality and efficiency.[2][6] As a medtech innovator, it exemplifies AI bridging evidence-based research with consumer-friendly apps, potentially accelerating global neuro-rehab standards.[1][7]
nyra health is poised for rapid scaling post-seed funding, prioritizing DACH growth, AI enhancements, and English-market entry to tap global demand.[1][2] Trends like AI biomarker tracking, tele-rehab normalization, and insurer adoption will propel it, with nyra.insights enabling data-driven advancements in dementia/long-term monitoring.[2][3] Its influence may evolve from regional leader to international player, redefining accessible neurotherapy—building on strong traction to deliver "revolutionary" patient outcomes at science's cutting edge.[1] This positions nyra health as a high-momentum bet in AI-health, directly tackling an escalating crisis with proven, scalable impact.
nyra health has raised $5.0M in total across 1 funding round.
nyra health's investors include Albion VC, Illuminate Financial Management, MassMutual Ventures.
nyra health has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $5.0M Seed | Albion VC, Illuminate Financial Management, MassMutual Ventures |